171 related articles for article (PubMed ID: 36053457)
1. Serine protease inhibitor Kazal type 1 (SPINK1) promotes proliferation, migration, invasion and radiation resistance in rectal cancer patients receiving concurrent chemoradiotherapy: a potential target for precision medicine.
Chen YT; Tseng TT; Tsai HP; Kuo SH; Huang MY; Wang JY; Chai CY
Hum Cell; 2022 Nov; 35(6):1912-1927. PubMed ID: 36053457
[TBL] [Abstract][Full Text] [Related]
2. Serine protease inhibitor Kazal type 1 (SPINK1) as a prognostic marker in stage IV colon cancer patients receiving cetuximab based targeted therapy.
Chen YT; Tsao SC; Tsai HP; Wang JY; Chai CY
J Clin Pathol; 2016 Apr; ():. PubMed ID: 27107100
[TBL] [Abstract][Full Text] [Related]
3. Serine peptidase inhibitor Kazal type I (SPINK1) promotes BRL-3A cell proliferation via p38, ERK, and JNK pathways.
Chang C; Zhao W; Luo Y; Xi L; Chen S; Zhao C; Wang G; Guo J; Xu C
Cell Biochem Funct; 2017 Aug; 35(6):339-348. PubMed ID: 28845526
[TBL] [Abstract][Full Text] [Related]
4. High SPINK4 Expression Predicts Poor Outcomes among Rectal Cancer Patients Receiving CCRT.
Chen TJ; Tian YF; Chou CL; Chan TC; He HL; Li WS; Tsai HH; Li CF; Lai HY
Curr Oncol; 2021 Jun; 28(4):2373-2384. PubMed ID: 34202399
[TBL] [Abstract][Full Text] [Related]
5. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
[TBL] [Abstract][Full Text] [Related]
6. Serine Protease Inhibitor Kazal Type 1 (SPINK1) Promotes Proliferation of Colorectal Cancer Through the Epidermal Growth Factor as a Prognostic Marker.
Chen YT; Tsao SC; Yuan SS; Tsai HP; Chai CY
Pathol Oncol Res; 2015 Sep; 21(4):1201-8. PubMed ID: 26037168
[TBL] [Abstract][Full Text] [Related]
7. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.
Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J
Front Immunol; 2022; 13():923031. PubMed ID: 35924241
[TBL] [Abstract][Full Text] [Related]
8. Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.
Ying HY; Gong CJ; Feng Y; Jing DD; Lu LG
J Dig Dis; 2017 Jun; 18(6):349-358. PubMed ID: 28544403
[TBL] [Abstract][Full Text] [Related]
9. Identification and Exploration of Serine Peptidase Inhibitor Kazal Type I (SPINK1) as a Potential Biomarker Correlated with the Progression of Non-Small Cell Lung Cancer.
Li D; Zhang X; Ding Z; Ai R; Shi L; Wang Z; He Q; Dong Y; Zhu Y; Ouyang W; He Y
Cell Biochem Biophys; 2022 Dec; 80(4):807-818. PubMed ID: 36194314
[TBL] [Abstract][Full Text] [Related]
10. The X-linked inhibitor of apoptosis protein is an independent prognostic marker for rectal adenocarcinoma after preoperative chemoradiotherapy.
Chen YT; Tsao SC; Tsai HP; Wang JY; Chai CY
Virchows Arch; 2016 May; 468(5):559-67. PubMed ID: 26915033
[TBL] [Abstract][Full Text] [Related]
11. High SPINK1 Expression Predicts Poor Prognosis and Promotes Cell Proliferation and Metastasis of Hepatocellular Carcinoma.
Huang K; Xie W; Wang S; Li Q; Wei X; Chen B; Hua Y; Li S; Peng B; Shen S
J Invest Surg; 2021 Sep; 34(9):1011-1020. PubMed ID: 32066292
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of SPINK1-positive prostate cancer.
Ateeq B; Tomlins SA; Laxman B; Asangani IA; Cao Q; Cao X; Li Y; Wang X; Feng FY; Pienta KJ; Varambally S; Chinnaiyan AM
Sci Transl Med; 2011 Mar; 3(72):72ra17. PubMed ID: 21368222
[TBL] [Abstract][Full Text] [Related]
13. The impact of physiological stress conditions on protein structure and trypsin inhibition of serine protease inhibitor Kazal type 1 (SPINK1) and its N34S variant.
Buchholz I; Nagel F; Klein A; Wagh PR; Mahajan UM; Greinacher A; Lerch MM; Mayerle J; Delcea M
Biochim Biophys Acta Proteins Proteom; 2020 Jan; 1868(1):140281. PubMed ID: 31525466
[TBL] [Abstract][Full Text] [Related]
14. Roles of serine protease inhibitor Kazal type 1 (SPINK1) in pancreatic diseases.
Ohmuraya M; Yamamura K
Exp Anim; 2011; 60(5):433-44. PubMed ID: 22041280
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 increases expression of serine protease inhibitor Kazal type 1 through STAT3 in colorectal adenocarcinoma.
Räsänen K; Lehtinen E; Nokelainen K; Kuopio T; Hautala L; Itkonen O; Stenman UH; Koistinen H
Mol Carcinog; 2016 Dec; 55(12):2010-2023. PubMed ID: 26663388
[TBL] [Abstract][Full Text] [Related]
16. Functional Roles of SPINK1 in Cancers.
Lin TC
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33916984
[TBL] [Abstract][Full Text] [Related]
17. SPINK1 promotes cell growth and metastasis of lung adenocarcinoma and acts as a novel prognostic biomarker.
Xu L; Lu C; Huang Y; Zhou J; Wang X; Liu C; Chen J; Le H
BMB Rep; 2018 Dec; 51(12):648-653. PubMed ID: 30545439
[TBL] [Abstract][Full Text] [Related]
18. High expression of serine protease inhibitor kazal type 1 predicts poor prognosis and promotes the progression and invasion of oral tongue squamous cell carcinoma.
Wang S; Sun Y; Shao D; Pan Y; Gao X; Zhao P; Liu Q; Shang G; Shang W; Fu Z; Sun Y
Arch Oral Biol; 2024 May; 164():106003. PubMed ID: 38781741
[TBL] [Abstract][Full Text] [Related]
19. miR-5089-5p suppresses castration-resistant prostate cancer resistance to enzalutamide and metastasis via miR-5089-5p/SPINK1/ MAPK/MMP9 signaling.
Wang ZC; Li Y; Wang KL; Wang L; You BS; Zhao DF; Liu ZQ; Fang RZ; Wang JQ; Zhang W; Zhang JM; Xu WH
Aging (Albany NY); 2020 Jul; 12(14):14418-14433. PubMed ID: 32694237
[TBL] [Abstract][Full Text] [Related]
20. Mutations in serine protease inhibitor Kazal type 1 are strongly associated with chronic pancreatitis.
Drenth JP; te Morsche R; Jansen JB
Gut; 2002 May; 50(5):687-92. PubMed ID: 11950817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
